Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LTP
LTP001 · 1 trial · 1 indication
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations and adverse events up to and including the end-of-study visit.
PVR is a hemodynamic variable of pulmonary circulation and is measured by right heart catheterization.
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations, treatment-emergent adverse events and discontinuations due to adverse events.
| Arm | Type | Description |
|---|---|---|
| LTP001 Dose 1 | EXPERIMENTAL | - |
| LTP001 Dose 2 | EXPERIMENTAL | - |
| LTP001 Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | matching placebo |
| Name | Type | Description |
|---|---|---|
| LTP | DRUG | LTP001 |
| Placebo | DRUG | Placebo |
Part A Inclusion Criteria: * Healthy males and non-child-bearing potential females Part A Exclusion Criteria: * Clinically significant ECG or cardiac abnormalities, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, o...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 5 | PHASE3 | selexipag, Macitentan |
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| IRulya Therapeutics Inc. | IRLA | 1 | PHASE2 | LAM-001 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
LTP001 is an investigational small molecule drug being developed by Novartis AG for pulmonary arterial hypertension, a form of high blood pressure in the arteries of the lungs. It is in Phase 1 clinical development and has not been approved by the FDA. It is also known as LTP.
LTP001 is being studied for the treatment of pulmonary arterial hypertension, a cardiovascular condition involving elevated pressure in the pulmonary arteries. The Phase 1 program also includes a healthy volunteer portion. Its safety and efficacy in patients have not yet been established.
LTP001 is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. Novartis is the sponsor of the clinical program evaluating the drug in healthy participants and in patients with pulmonary arterial hypertension.
LTP001 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any indication. The single Phase 1 trial is currently recruiting participants.
LTP001 is being evaluated in one Phase 1 trial, NCT06649110, titled A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B). The trial is recruiting, is randomized, double-blind, and placebo-controlled, and plans to enroll 232 participants across 18 countries.
Yes, LTP001 is also referred to as LTP. Both names refer to the same investigational small molecule developed by Novartis AG for pulmonary arterial hypertension. Searches for either name point to the same Phase 1 program.